RCT: Trametinib improves progression-free survival compared to standard of care in patients with recurrent low-grade serous ovarian cancer.

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial – The Lancet

News Release: Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma – M. D. Anderson Cancer Center

Commentary on Twitter

Trial findings suggest MEK inhibitor, trametinib, represents new standard-of-care option for patients with recurrent low-grade serous carcinoma. https://t.co/69glZZdrZF pic.twitter.com/UHeccCj1Rn

— The Lancet (@TheLancet) February 10, 2022